Generic Drug User Fee Amendments

Why It Matters

GDUFA III secures predictable FDA funding, accelerating generic‑drug reviews and preserving affordable patient access, while the heightened fees increase compliance costs for manufacturers.

Key Takeaways

• FY2025 ANDA fee rises to $321,920.
• Large program fee exceeds $1.9 million per company.
• Foreign facilities pay $15,000 premium over domestic.
• Non‑payment triggers arrears list and submission bans.
• Fees due October 1; penalties start after 20 days.

Pulse Analysis

The Generic Drug User Fee Amendments, first enacted in 2012, were designed to give the FDA a stable financial base for reviewing abbreviated new drug applications (ANDAs). By re‑authorizing GDUFA through 2027, Congress reaffirmed its commitment to a transparent, predictable fee structure that supports the agency’s mission of delivering safe, high‑quality, and affordable generics. GDUFA III builds on earlier iterations, incorporating stakeholder feedback and expanding fee categories to cover both applicant programs and manufacturing facilities.

Under GDUFA III, FY 2025 and FY 2026 fee schedules reflect a modest but notable increase across the board. The ANDA filing fee climbs to $321,920, while program fees for large, medium, and small portfolios range from $189,166 to $1,891,664. Facility fees differentiate domestic and foreign sites, adding a $15,000 surcharge for overseas inspections. These adjustments aim to offset rising inspection costs and to fund performance goals such as reduced review times. For manufacturers, the new rates translate into higher annual operating expenses, prompting strategic portfolio reviews and potential consolidation to stay within lower fee tiers.

Compliance risk has also intensified. Missing the October 1 deadline triggers a 20‑day grace period after which applicants face arrears listings, bans on new ANDA submissions, and the misbranding of existing products. Such penalties can disrupt supply chains and erode market share, especially for smaller firms. Looking ahead, industry observers anticipate GDUFA IV discussions for FY 2028‑2032, where fee structures may further evolve in response to inflation and FDA resource needs. Companies that proactively manage fee obligations and align their filing strategies with GDUFA’s performance metrics will be better positioned to maintain market access and capitalize on the growing generic drug landscape.